Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2003
03/26/2003EP1181010A4 Pharmaceutical chewing gum formulations
03/26/2003EP1175420B1 Process for preparing n6-substituted deaza-adenosine derivatives
03/26/2003EP1173215A4 Over-coated chewing gum formulations
03/26/2003EP1140917B1 S-oxide lipid lowering compounds
03/26/2003EP1098893B1 Cyclic compounds useful in the treatment of dyslipidemia, atherosclerosis and diabetes, pharmaceutical compositions and preparation process
03/26/2003EP1028717B1 Unsubstituted polydiallylamine for treating hypercholesterolemia
03/26/2003EP1027325B1 Lipophilic diesters of chelating agents
03/26/2003EP0998477B1 Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents
03/26/2003EP0977735B1 Vitronectin receptor antagonists
03/26/2003EP0930310B1 Isocoumarin derivatives and use thereof in drugs
03/26/2003EP0863757B1 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
03/26/2003EP0847240B1 Novel embolizing compositions
03/26/2003EP0841926B1 Endothelin receptor antagonists
03/26/2003EP0833819B1 Novel n-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3yl)-3-amides
03/26/2003EP0804229B1 Use of amlodipine, a salt thereof or felodipin in combination with an ace inhibitor in the manufacture of a medicament for the treatment of nonischemic congestive heart failure
03/26/2003CN1406283A Method of purifying a fermentation broth
03/26/2003CN1406243A Memno peptides, a process for their preparation and their use
03/26/2003CN1406230A 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
03/26/2003CN1406229A Pyrimidine compounds
03/26/2003CN1406227A Aryl fused azapolycy clic compounds
03/26/2003CN1406226A Novel malonic acid derivatives, process for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them
03/26/2003CN1406225A Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
03/26/2003CN1406134A Drugs for ameliorating retinal function
03/26/2003CN1406132A Method for treating or inhibiting cellular injury or cell death
03/26/2003CN1406127A Thiazolium compounds and treatments of disorders associated with protein aging
03/26/2003CN1405164A Corter pseudolaricis acid derivatives, preparation method and use thereof
03/26/2003CN1404877A Blood-platelet specific mosaic immune globulin and its using method
03/26/2003CN1404862A Compound blood-pressure reducing medicine
03/26/2003CN1404847A Medicine for treating sequel resulted from cardio-cerebral blood-vessel diseases
03/26/2003CN1404839A Notoginseng total saponin oral liquor
03/26/2003CN1103815C Thrombin mutants
03/26/2003CN1103780C Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
03/26/2003CN1103775C Vitronectin receptor antagonists, their preparation and use
03/26/2003CN1103772C Novel 2,3-disubstituted-4 (3H)-quinazolinone
03/26/2003CN1103590C Use of thiazolidinediones to prevent or delay on set of NIDDM
03/26/2003CA2423902A1 Benzodiazepine derivative
03/25/2003US6538149 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo [1,2-g]chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
03/25/2003US6538144 P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparation and use
03/25/2003US6538121 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
03/25/2003US6538116 For therapy of inflammatory or painful disorder
03/25/2003US6538038 A method of treating a warm-blooded animal having a vascular proliferative disorder, comprising administering, to the animal, an amount of a prodrug of a tubulin binding agent, other than combretastatin A4 disodium phosphate to achieve
03/25/2003US6538026 A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl
03/25/2003US6538024 Felbamate derived compounds
03/25/2003US6538021 Method for producing luteolin and luteolin derivatives
03/25/2003US6538017 Anticoagulants; cardiovascular disorders; central nervous system disorders
03/25/2003US6538012 Calcium channel blocker and can be used to treat or prevent angina or hypertension.
03/25/2003US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents
03/25/2003US6537995 Heterocyclic carboxamides
03/25/2003US6537992 Regulation of organic nitrate tolerance
03/25/2003US6537987 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
03/25/2003US6537984 Contacting a targeted solid tumor cell population with a combination of a vinca alkaloid selected from vinblastine, vincristine, vinorelbine, and a triptolide in combination dosage to reduce the targeted tumor cell population
03/25/2003US6537978 Oral administration of effective amounts of forms of hyaluronic acid
03/25/2003US6537974 Method of treating arrhythmias
03/25/2003US6537969 Nutritional supplement for cerebral metabolic insufficiencies
03/25/2003US6537775 Gene involved in cadasil, method of diagnosis and therapeutic application
03/25/2003US6537203 Cardiac disease treatment and device
03/25/2003CA2224093C Human vascular endothelial growth factor 2
03/25/2003CA2149052C Dry mix formulation for bisphosphonic acids
03/21/2003WO2002026702A1 Phenoxyphenyl alkane sulfonates
03/21/2003CA2423171A1 Phenoxyphenyl alkane sulfonates
03/20/2003WO2003023407A1 Methods of screening molecules that are used to prevent cardiovascular diseases
03/20/2003WO2003023066A1 Expression profiling in the intact human heart
03/20/2003WO2003023048A2 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)
03/20/2003WO2003023018A2 A method for isolating, culturing and differentiating intestinal stem cells for therapeutic use
03/20/2003WO2003023014A2 Human ion channels
03/20/2003WO2003023008A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/20/2003WO2003022997A2 Human tissue urokinase type plasminogen activator formulation
03/20/2003WO2003022882A2 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
03/20/2003WO2003022877A1 Crystal structure of baff, and use thereof in drug design
03/20/2003WO2003022860A1 Synthetic heparin pentasaccharides
03/20/2003WO2003022852A2 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
03/20/2003WO2003022849A1 Carbazole derivatives and their use as npy5 receptor antagonists
03/20/2003WO2003022842A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003WO2003022840A1 Pyridine derivatives as raf kinase inhibitors
03/20/2003WO2003022837A1 Heterocycle-carboxamide derivatives as raf kinase inhibitors
03/20/2003WO2003022836A1 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors
03/20/2003WO2003022833A1 Pyridylfurans and pyrroles as raf kinase inhibitors
03/20/2003WO2003022832A1 Pyridylfurans and pyrroles as raf kinase inhibitors
03/20/2003WO2003022830A1 Benzothiepine ileal bile acid transport inhibitors
03/20/2003WO2003022821A1 Heterocycle derivative having 20-hete-producing enzyme inhibitory activity
03/20/2003WO2003022814A1 Indole derivatives
03/20/2003WO2003022813A1 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient
03/20/2003WO2003022809A2 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
03/20/2003WO2003022801A1 Reverse hydroxamic acid derivatives
03/20/2003WO2003022360A2 Thermotherapy via targeted delivery of nanoscale magnetic particles
03/20/2003WO2003022324A1 Medical devices containing rapamycin analogs
03/20/2003WO2003022292A1 Oral pharmaceutical formulation containing active carbon and use of the same
03/20/2003WO2003022291A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
03/20/2003WO2003022287A1 USE OF 3β-HYDROXY-5-SPIROSTENE AS DRUGS FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES OR CONDITIONS FOR INHIBITION OF TUMORS AND DECREASING OF BLOOD LIPIDS
03/20/2003WO2003022286A1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
03/20/2003WO2003022285A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions
03/20/2003WO2003022284A1 Methods of treating pulmonary disease
03/20/2003WO2003022277A1 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
03/20/2003WO2003022276A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers
03/20/2003WO2003022273A1 Methods of treating cytokine mediated diseases
03/20/2003WO2003022270A1 Transdermal administration of an enalapril ester
03/20/2003WO2003022266A1 Hypoestoxides, derivatives and agonists thereof for use as inhibitors of angiongenesis
03/20/2003WO2003022259A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003WO2003022242A1 Preparation of sustained release pharmaceutical composition
03/20/2003WO2003004046A3 Use of xaa-pro peptidases for the treatment of substance p-related disorders
1 ... 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 ... 1595